Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vascular Biogenics's share price is €0.00.
Vascular Biogenics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.01. Hence, Vascular Biogenics's PS Ratio for today is 0.00.
The historical rank and industry rank for Vascular Biogenics's PS Ratio or its related term are showing as below:
STU:0VB'
s PS Ratio Range Over the Past 10 Years
Min: 1.2 Med: 65.5 Max: 261.25
Current: 25.83
During the past 11 years, Vascular Biogenics's highest PS Ratio was 261.25. The lowest was 1.20. And the median was 65.50.
STU:0VB's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.22
vs STU:0VB: 25.83
Vascular Biogenics Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Vascular Biogenics was -25.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -46.20% per year.
During the past 11 years, Vascular Biogenics's highest 3-Year average Revenue per Share Growth Rate was -12.60% per year. The lowest was -65.40% per year. And the median was -20.60% per year.
Back to Basics: PS Ratio
Vascular Biogenics (STU:0VB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vascular Biogenics PS Ratio Related Terms
Vascular Biogenics PS Ratio Historical Data
* Premium members only.
The historical data trend for Vascular Biogenics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vascular Biogenics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Biogenics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vascular Biogenics's Share Price of today is €0.00. Vascular Biogenics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vascular Biogenics (STU:0VB) has a PS Ratio of 0.00 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vascular Biogenics and its competitors. Over the past decade, Vascular Biogenics' PS Ratio has ranged from 1.20 to 261.25.
Is Vascular Biogenics' PS Ratio too high?
Vascular Biogenics' current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 261.25. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' PS Ratio compare to MBIO and GNPX?
Vascular Biogenics' PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.22. Historically, Vascular Biogenics' own PS Ratio has ranged from 1.20 to 261.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vascular Biogenics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vascular Biogenics's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current PS Ratio is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0VB has been successfully added to your 
